NanoRepro AG Logo

NanoRepro AG

Develops and distributes rapid diagnostic self-tests for early disease detection.

NN6 | F

Overview

Corporate Details

ISIN(s):
DE0006577109
LEI:
3912008FCA63AGIMEV74
Country:
Germany
Address:
UNTERGASSE 8, 35037 MARBURG
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

NanoRepro AG is an innovative leader in the development, manufacturing, and distribution of CE-marked rapid diagnostic tests (self-tests) and food supplements. The company serves both home and professional markets, domestically and internationally. Its product portfolio is designed to provide rapid and accurate results for early disease detection and preventive healthcare. Key product categories include family planning, disease detection, food intolerances, allergies, and infectious diseases. The company's stated goal is to provide accuracy in self-diagnostics for rapid disease detection.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-05 00:00
Annual Report
Datum:05.09.2025
German 442.2 KB
2025-08-20 14:30
Regulatory News Service
NanoRepro AG: Aktuelle GBC-Studie mit Kursziel 4,50 Euro
German 13.2 KB
2025-08-05 14:00
Director's Dealing
NanoRepro AG: Lisa Jungst, buy
German 6.0 KB
2025-07-21 00:00
Annual / Quarterly Financial Statement
Berichtigung der Veröffentlichung vom 14.03.2025
German 15.0 KB
2025-07-18 15:00
Earnings Release
NanoRepro AG: Endgultige Jahreszahlen 2024 - NanoRepro bleibt auf Wachstumskurs
German 14.4 KB
2025-05-26 14:01
Director's Dealing
NanoRepro AG: Dr. Olaf Stiller, buy
German 6.0 KB
2025-05-19 12:01
Director's Dealing
NanoRepro AG: Dr. Olaf Stiller, buy
German 6.0 KB
2025-05-08 15:01
Director's Dealing
NanoRepro AG: Dr. Olaf Stiller, buy
German 5.9 KB
2025-04-29 14:00
M&A Activity
NanoRepro AG: NanoRepro AG investiert in Kaltplasma-Technologie und baut ihre M…
German 11.4 KB
2025-04-16 14:00
Regulatory News Service
NanoRepro AG: NanoRepro erhalt EU-Qualitatsmanagementbescheinigung nach Verordn…
German 8.9 KB
2025-03-27 15:46
Director's Dealing
NanoRepro AG: Dr. Olaf Stiller, buy
German 5.9 KB
2025-03-26 16:01
Director's Dealing
NanoRepro AG: Dr. Olaf Stiller, buy
German 5.9 KB
2025-03-14 00:00
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 34.7 KB
2025-02-26 09:45
Director's Dealing
NanoRepro AG: Dr. Olaf Stiller, buy
German 6.0 KB
2025-02-25 09:45
Director's Dealing
NanoRepro AG: Dr. Olaf Stiller, buy
German 6.0 KB

Automate Your Workflow. Get a real-time feed of all NanoRepro AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for NanoRepro AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-02-25 Stiller, Dr. Olaf Supervisory board Buy None 14,506.24 EUR
2025-02-17 Stiller, Dr. Olaf Supervisory board Buy None 18,750.00 EUR
2024-10-29 Stiller, Dr. Olaf Supervisory board Buy None 17,300.00 EUR
2024-10-22 Stiller, Dr. Olaf Supervisory board Buy None 8,949.96 EUR
2024-10-22 Stiller, Dr. Olaf Supervisory board Buy None 8,500.00 EUR
2024-10-21 Stiller, Dr. Olaf Supervisory board Buy None 8,750.00 EUR
2024-10-21 Stiller, Johanna Close relation Buy None 3,759.00 EUR
2024-08-30 ASS GmbH Close relation Buy None 30,644.30 EUR
2024-07-25 Stiller, Dr. Olaf Supervisory board Buy None 3,279.18 EUR
2024-07-24 Jüngst, Lisa Board Buy None 21,762.00 EUR

Peer Companies

Company Country Ticker View
Fine Foods & Pharmaceuticals Ntm Logo
Contract development & manufacturing of oral solids for pharma, nutraceutical & cosmetic sectors.
Italy FF
Formycon AG Logo
Develops cost-effective biosimilars for ophthalmology, immunology, and other chronic diseases.
Germany FYB
Friulchem Logo
CDMO for animal health, providing vet pharma & supplement solutions for pets and livestock.
Italy FCM
Fuji Pharma Co.,Ltd. Logo
Specializes in hormone medicines for ob/gyn, injectables, and contract manufacturing.
Japan 4554
Fuso Pharmaceutical Industries,Ltd. Logo
Manufactures essential pharmaceuticals like dialysis drugs, infusions, and injections for healthcare.
Japan 4538
FutureChem Co., Ltd. Logo
Develops radiopharmaceuticals & diagnostic agents for cancer, Alzheimer's, and Parkinson's disease.
South Korea 220100
Future Medicine  Co., Ltd. Logo
Clinical-stage biopharma developing novel synthetic drugs for inflammation, fibrosis, and oncology.
South Korea 341170
Develops long-acting injectable therapies for chronic diseases and cancer.
South Korea 456160
Gabather AB Logo
Developing novel GABAA receptor drugs for neuropsychiatric disorders.
Sweden GABA
Galapagos NV Logo
Biotech firm developing novel CAR-T cell therapies for oncology via a rapid delivery platform.
Belgium GLPG

Talk to a Data Expert

Have a question? We'll get back to you promptly.